All In Biotech

Drug Trial Radar · NCT07431281

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,130

Planned (sponsor's estimate)

Start

Feb 3, 2026

Primary completion

Aug 16, 2029

Study completion Oct 27, 2031

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Esophageal Cancer

Interventions

  • Sonesitatug vedotinDrug

    Intravenous

  • RilvegostomigDrug

    Intravenous

  • NivolumabDrug

    Intravenous

  • CapecitabineDrug

    Oral

  • 5-FluorouracilDrug

    Intravenous

  • OxaliplatinDrug

    Intravenous

  • ZolbetuximabDrug

    Intravenous

  • LeucovorinDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) (Cohort 1 and Cohort 2)Time frame: Up to approximately 5 years
  2. Overall Survival (OS) (Cohort 1)Time frame: Up to approximately 5 years

Locations

314 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Not yet recruiting

  • Research Site

    Mobile, Alabama · Not yet recruiting

  • Research Site

    Anchorage, Alaska · Not yet recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Springdale, Arkansas · Not yet recruiting

  • Research Site

    Duarte, California · Not yet recruiting

  • Research Site

    Fountain Valley, California · Recruiting

  • Research Site

    Fullerton, California · Not yet recruiting

  • Research Site

    Irvine, California · Recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Los Alamitos, California · Not yet recruiting

  • Research Site

    Orange, California · Recruiting

  • Research Site

    Walnut Creek, California · Recruiting

  • Research Site

    Whittier, California · Not yet recruiting

  • Research Site

    Denver, Colorado · Not yet recruiting

  • Research Site

    Lone Tree, Colorado · Recruiting

  • Research Site

    New Haven, Connecticut · Withdrawn

  • Research Site

    Newark, Delaware · Not yet recruiting

  • Research Site

    Washington D.C., District of Columbia · Withdrawn

  • Research Site

    Fort Myers, Florida · Withdrawn

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Orlando, Florida · Not yet recruiting

  • Research Site

    St. Petersburg, Florida · Withdrawn

  • Research Site

    West Palm Beach, Florida · Withdrawn

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Atlanta, Georgia · Withdrawn

  • Research Site

    Macon, Georgia · Recruiting

  • Research Site

    Newnan, Georgia · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Niles, Illinois · Recruiting

  • Research Site

    Zion, Illinois · Not yet recruiting

  • Research Site

    Indianapolis, Indiana · Recruiting

  • Research Site

    Waukee, Iowa · Not yet recruiting

  • Research Site

    Lexington, Kentucky · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Not yet recruiting

  • Research Site

    Silver Spring, Maryland · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Burlington, Massachusetts · Not yet recruiting

Showing 40 of 314 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.